Integra LifeSciences Reports First Quarter 2018 Financial Results

- April 25th, 2018

Integra LifeSciences (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2018. As quoted in the press release: Total revenues for the first quarter 2018 were $357.1 million, reflecting an increase of 38.1%, over the first quarter of 2017. Sales in the Codman Specialty Surgical segment increased 51.1% … Continued

Integra LifeSciences (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2018.

As quoted in the press release:

Total revenues for the first quarter 2018 were $357.1 million, reflecting an increase of 38.1%, over the first quarter of 2017. Sales in the Codman Specialty Surgical segment increased 51.1% compared to the first quarter of 2017, driven by the acquired revenues from Codman Neurosurgery, as well as strong capital sales of CUSA® Clarity. Sales in the Orthopedics and Tissue Technologies segment increased 18.2%, reflecting a full quarter of sales from Derma Sciences and strength in both our regenerative technologies, as well as our ankle and shoulder portfolios.

Total organic revenues increased 3.0% over the first quarter of 2017, excluding acquisitions, divestitures and the effect of currency exchange rates, slightly ahead of our expectations.

“We are off to a strong start in 2018, which gives us the confidence to increase our full-year 2018 financial guidance,” said Peter Arduini, Integra’s president and chief executive officer. “We are pleased with the progress of the Codman integration and continued progress in the OTT channel expansion. We expect to see organic growth accelerate in the remainder of the year.”

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Leave a Reply